A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle
Open Access
- 7 October 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Abstract
Seasonal influenza virus and human coronaviruses (HCoVs) represent persistent threats to global public health, with current antiviral agents limited by narrow-spectrum activity and the emergence of drug resistance. Multi-stage and multi-target antiviral agents enhance therapeutic efficacy and overcome drug resistance versus single-target therapies by inhibiting multiple key steps of the viral life cycle, such as entry, replication, and release. Here, we characterize a novel ursodeoxycholic acid (UCDA) derivative (U-BSA) as a broad-spectrum antiviral candidate effective against influenza A viruses (H1N1 and H3N2), HCoVs (including HCoV-OC43 and other pseudovirus models), and respiratory syncytial virus (RSV). In vitro , U-BSA exhibited inhibitory activity against H1N1 (half-maximal effective concentration [EC 50 ] = 4.10 µM; selectivity index [SI] > 50), H3N2 (EC 50 = 2.41 µM, SI > 40), HCoV-OC43 (EC₅₀ = 9.66 µM, SI > 20), and RSV (EC 50 = 6.01 µM, SI > 12). Furthermore, U-BSA conferred significant protection in a lethal influenza infection model in vivo . Mechanistic studies demonstrated that U-BSA interferes with multiple viral life cycles: it disrupts viral attachment, inhibits entry by blocking endosomal acidification, and suppresses virion release. U-BSA rescues virus-induced membrane lipid disorder, revealing that modulation of host membrane homeostasis serves as a critical upstream mechanism underlying its multiphasic antiviral inhibition. This multi-target mode of action represents a significant advance in antiviral strategy, highlighting U-BSA as a promising candidate for developing broad-spectrum antivirals against pan-respiratory virus.Keywords
Funding Information
- Major Scientific and Technological Projects of Guangdong Province (2023B1111050008)
- National Natural Science Foundation of China (82130101)
- National Natural Science Foundation of China (82504811)
- Basic and Applied Basic Research Foundation of Guangdong Province (2025A1515010495)
- Post Scientist Fund awarded by Chinese Academy of Traditional Chinese Medicine (ZZ13-035-02)
This publication has 34 references indexed in Scilit:
- Remdesivir for the Treatment of Human Coronavirus OC43 EncephalitisJournal of Medical Virology, 2025
- An Inhalable Nanoshield for Effective Prevention of Influenza Virus InfectionsACS Nano, 2024
- C-Laurdan: Membrane Order Visualization of HEK293t Cells by Confocal Microscopy2023
- InfluenzaThe Lancet, 2022
- An outlook on potential protein targets of COVID-19 as a druggable siteMolecular Biology Reports, 2022
- Estimates of global seasonal influenza-associated respiratory mortality: a modelling studyThe Lancet, 2018
- Interaction of Cytotoxic and Cytoprotective Bile Acids with Model Membranes: Influence of the Membrane CompositionLangmuir, 2015
- Broad-spectrum antivirals against viral fusionNature Reviews Microbiology, 2015
- Quantitative imaging of membrane lipid order in cells and organismsNature Protocols, 2011
- Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemicNature, 2009